|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-31
|
|
pubmed:abstractText |
Indacaterol is a novel, once daily, inhaled ultra-long-acting ??-agonist for the treatment of chronic obstructive pulmonary disease (COPD). Here we compared the 24-h spirometry profile of once daily indacaterol 300 ?g with that of placebo and twice daily salmeterol 50 ?g in patients with COPD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1522-9629
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
162-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20619353-Adrenergic beta-2 Receptor Agonists,
pubmed-meshheading:20619353-Aged,
pubmed-meshheading:20619353-Cross-Over Studies,
pubmed-meshheading:20619353-Double-Blind Method,
pubmed-meshheading:20619353-Female,
pubmed-meshheading:20619353-Forced Expiratory Volume,
pubmed-meshheading:20619353-Humans,
pubmed-meshheading:20619353-Indans,
pubmed-meshheading:20619353-Male,
pubmed-meshheading:20619353-Middle Aged,
pubmed-meshheading:20619353-Pulmonary Disease, Chronic Obstructive,
pubmed-meshheading:20619353-Quinolones
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Sustained 24-hour efficacy of once daily indacaterol (300 ?g) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
|
|
pubmed:affiliation |
North Carolina Clinical Research, Raleigh, NC, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
